Genmab out-licenses global rights for zanolimumab to TenX Biopharma

Danish biotechnology firm Genmab has closed a license agreement granting exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4 to Philadelphia, USA-based cancer drug specialist TenX Biopharma.

Under the terms of the deal, Genmab receives a payment of $4.5 million and will be entitled to milestones and royalties on sales of zanolimumab. TenX Biopharma will be responsible for all future costs of developing, manufacturing and commercializing zanolimumab.

'Zanolimumab has promise for treatment of patients with T cell cancers, and potential in other cancer types for which existing therapies are inadequate,' said Gardiner Smith, chief executive of TenX Biopharma, who added: 'We are building a pipeline of new medicines for high unmet need, with a focus on the patient through business efficiency.'